Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies-Reference-Cited by-同舟云学术

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

Published:2020-05-14 Issue:2 Volume:9 Page:443-457
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Bertolotto Antonio,Arroyo Rafael,Celius Elisabeth G.,Comi Giancarlo,Havrdova Eva Kubala,Honeycutt William David,Hunter Samuel F.,Izquierdo Guillermo,Kornek Barbara,Miller Tamara,Mitsikostas Dimos D.,Singer Barry A.,Ziemssen Tjalf,Chung Luke,Daizadeh Nadia,Afsar Salman,Hashemi Lobat,Senior Peter

Funder

Sanofi

Bayer HealthCare Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

http://link.springer.com/content/pdf/10.1007/s40120-020-00191-7.pdf

Reference27 articles.

1. Berger JR. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies. Am J Manag Care. 2011;17(Suppl 5):S146–53.

2. Sorensen PS. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis. J Neurol Sci. 2011;311(Suppl 1):S29–34.

3. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819–28.

4. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829–39.

5. Fox EJ, Brassat D, Alroughani R, et al. Alemtuzumab provides durable efficacy over 6 years in patients with active relapsing-remitting multiple scle.rosis and an inadequate response to prior therapy in the absence of continuous treatment (CARE-MS II). Neurology. 2017;88(Suppl 16):S24.006.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model;Multiple Sclerosis Journal;2024-06-10

2. Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2023-01

3. Predicting improvement of quality of life and mental health over 18-months in multiple sclerosis patients;Multiple Sclerosis and Related Disorders;2021-08

4. Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?;Expert Review of Neurotherapeutics;2020-10-10

5. The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis;Cells;2020-06-03